Cargando…
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
DNA damage response (DDR) deficiencies result in genome instability, which is one of the hallmarks of cancer. Poly (ADP-ribose) polymerase (PARP) enzymes take part in various DDR pathways, determining cell fate in the wake of DNA damage. PARPs are readily druggable and PARP inhibitors (PARPi) agains...
Autores principales: | Hunia, Jaromir, Gawalski, Karol, Szredzka, Aleksandra, Suskiewicz, Marcin J., Nowis, Dominika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751342/ https://www.ncbi.nlm.nih.gov/pubmed/36533080 http://dx.doi.org/10.3389/fmolb.2022.1073797 |
Ejemplares similares
-
Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020) -
A Systematic Pan-Cancer Analysis of CASP3 as a Potential Target for Immunotherapy
por: Zhou, Zheng, et al.
Publicado: (2022) -
Molecular Mechanism of Selective Binding of NMS-P118 to PARP-1 and PARP-2: A Computational Perspective
por: Wang, Ran, et al.
Publicado: (2020) -
Development of Personalized Signature Based on the Immune Landscape to Predict the Prognosis of Osteosarcoma and the Response to Immunotherapy and Targeted Therapy
por: Feng, Xiaofei, et al.
Publicado: (2022) -
RelB is a potential molecular biomarker for immunotherapy in human pan-cancer
por: Wu, Jintao, et al.
Publicado: (2023)